NCT03388190 2026-02-13
METIMMOX
University Hospital, Akershus
Phase 2 Completed
Clinical Trials
23 trialsNCT05217069 2025-04-16
FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC
Ludwig-Maximilians - University of Munich
Phase 2 Completed
NCT02723955 2024-12-27
Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)
GlaxoSmithKline
Phase 1 Completed
NCT03665441 2022-10-18
Trybeca-1
ERYtech Pharma
Phase 3 Completed
NCT02625610 2022-06-09
Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)
EMD Serono
Phase 3 Completed
NCT02178709 2022-04-19
A Phase II Study of Neoadjuvant FOLFIRINOX
Indiana University
Phase 2 Completed
NCT01362374 2022-01-12
Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors
Genentech, Inc.
Phase 1 Completed
NCT01660711 2021-11-08
A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma
Endeavor Health
Phase 2 Completed
NCT01633970 2020-10-08
A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Phase 1 Completed
NCT01653470 2020-01-28
Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors
Bristol-Myers Squibb
Phase 1 Completed
NCT01274624 2018-12-19
Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer
Oncolytics Biotech
Phase 1 Completed
NCT02620423 2018-09-13
Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma
Oncolytics Biotech
Phase 1 Completed
NCT02324452 2018-05-11
Safety, Feasibility and Cost-effectiveness of Genotype-directed Individualized Dosing of Fluoropyrimidines
The Netherlands Cancer Institute
Phase NA Completed
NCT00500292 2018-01-25
A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer
Sanofi
Phase 2 Completed
NCT01472029 2017-06-19
HerFLOT
AIO-Studien-gGmbH
Phase 2 Completed
NCT00548548 2017-06-14
AVAGAST
Genentech, Inc.
Phase 3 Completed
NCT00246103 2017-02-23
Phase I Trial of Valproic Acid and Epirubicin in Solid Tumor Malignancies
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02640365 2017-01-31
DOUBLIRI
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 1 Completed
NCT00499850 2016-08-25
Phase I FOLFOX Combination
Sanofi
Phase 1 Completed
NCT00507091 2016-08-25
Phase I Irinotecan, 5-Fluorouracil and Leucovorin Combination
Sanofi
Phase 1 Completed
NCT00557557 2015-12-28
Safety Study of Oxaliplatin and 5-fluorouracil Followed by FUDR for Unresectable Colorectal Liver Metastases
University of Pittsburgh
Phase 1 Completed
NCT00838370 2014-03-04
Pharmacogenomic and Pharmacokinetic Safety and Cost-saving Analysis in Patients Treated With Fluoropyrimidines
The Netherlands Cancer Institute
Phase 1 Completed
NCT00139243 2008-06-04
Study of Taxotere, Cisplatin, 5-Fluorouracil, and Leucovorin for Squamous Cell Carcinoma of the Head and Neck
Dana-Farber Cancer Institute
Phase 1/2 Completed